BR0110492A - Composto, composição farmacêutica que compreende esse composto, processo para a preparação de composição farmacêutica, utilização do composto e processo para a preparação do composto - Google Patents
Composto, composição farmacêutica que compreende esse composto, processo para a preparação de composição farmacêutica, utilização do composto e processo para a preparação do compostoInfo
- Publication number
- BR0110492A BR0110492A BR0110492-6A BR0110492A BR0110492A BR 0110492 A BR0110492 A BR 0110492A BR 0110492 A BR0110492 A BR 0110492A BR 0110492 A BR0110492 A BR 0110492A
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- pharmaceutical composition
- preparing
- diabetes
- useful
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 8
- 238000004519 manufacturing process Methods 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- 239000012190 activator Substances 0.000 abstract 1
- 150000001469 hydantoins Chemical class 0.000 abstract 1
- 230000003914 insulin secretion Effects 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
"COMPOSTO, COMPOSIçãO FARMACêUTICA QUE COMPREENDE ESSE COMPOSTO, PROCESSO PARA A PREPARAçãO DE COMPOSIçãO FARMACêUTICA, UTILIZAçãO DO COMPOSTO E PROCESSO PARA A PREPARAçãO DO COMPOSTO". Expõem-se compostos de hidantoína os quais são ativos como ativadores de glicoquinase para aumentarem a secreção de insulina que os torna de utilidade para tratamento de diabetes do tipo II.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20149800P | 2000-05-03 | 2000-05-03 | |
| PCT/EP2001/004555 WO2001083478A2 (en) | 2000-05-03 | 2001-04-23 | Hydantoin-containing glucokinase activators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0110492A true BR0110492A (pt) | 2003-04-08 |
Family
ID=22746054
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0110492-6A BR0110492A (pt) | 2000-05-03 | 2001-04-23 | Composto, composição farmacêutica que compreende esse composto, processo para a preparação de composição farmacêutica, utilização do composto e processo para a preparação do composto |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US6583288B2 (pt) |
| EP (1) | EP1280801B1 (pt) |
| JP (1) | JP3842131B2 (pt) |
| KR (1) | KR100505312B1 (pt) |
| CN (1) | CN1209361C (pt) |
| AR (1) | AR034253A1 (pt) |
| AT (1) | ATE304011T1 (pt) |
| AU (2) | AU5227001A (pt) |
| BR (1) | BR0110492A (pt) |
| CA (1) | CA2407428C (pt) |
| DE (1) | DE60113247T2 (pt) |
| DK (1) | DK1280801T3 (pt) |
| EC (1) | ECSP014055A (pt) |
| ES (1) | ES2248309T3 (pt) |
| MX (1) | MXPA02010746A (pt) |
| PE (1) | PE20011313A1 (pt) |
| PT (1) | PT1280801E (pt) |
| UY (1) | UY26689A1 (pt) |
| WO (1) | WO2001083478A2 (pt) |
| ZA (1) | ZA200208370B (pt) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5227001A (en) * | 2000-05-03 | 2001-11-12 | Hoffmann La Roche | Hydantoin-containing glucokinase activators |
| US6482951B2 (en) | 2000-12-13 | 2002-11-19 | Hoffmann-La Roche Inc. | Isoindolin-1-one glucokinase activators |
| SE0102299D0 (sv) | 2001-06-26 | 2001-06-26 | Astrazeneca Ab | Compounds |
| SE0102764D0 (sv) | 2001-08-17 | 2001-08-17 | Astrazeneca Ab | Compounds |
| PL370989A1 (en) | 2001-12-21 | 2005-06-13 | Novo Nordisk A/S | Amide derivatives as gk activators |
| RU2340605C2 (ru) | 2002-06-27 | 2008-12-10 | Ново Нордиск А/С | Арилкарбонильные производные в качестве терапевтических средств |
| AU2003243921B2 (en) | 2002-06-27 | 2009-05-07 | Novo Nordisk A/S | Aryl carbonyl derivatives as therapeutic agents |
| BR0314864A (pt) | 2002-10-03 | 2005-08-02 | Novartis Ag | Compostos orgânicos |
| GB0226931D0 (en) | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
| MY141521A (en) * | 2002-12-12 | 2010-05-14 | Hoffmann La Roche | 5-substituted-six-membered heteroaromatic glucokinase activators |
| US7262196B2 (en) * | 2003-02-11 | 2007-08-28 | Prosidion Limited | Tri(cyclo) substituted amide glucokinase activator compounds |
| PL378117A1 (pl) | 2003-02-11 | 2006-03-06 | Prosidion Limited | Tricyklopodstawione związki amidowe |
| CN1910166B (zh) * | 2004-01-06 | 2012-01-04 | 诺和诺德公司 | 杂芳基脲及其作为葡糖激酶活化剂的用途 |
| BRPI0506662B8 (pt) * | 2004-01-06 | 2021-05-25 | Novo Nordisk As | compostos ativadores de glucoquinase |
| US7781451B2 (en) | 2004-04-02 | 2010-08-24 | Novartis Ag | Thiazolopyridine derivatives, pharmaceut ical conditions containing them and methods of treating glucokinase mediated conditions |
| BRPI0509573A (pt) | 2004-04-02 | 2007-09-25 | Novartis Ag | derivados de sulfonamida-tiazolpiridina como ativadores de glicocinase úteis para o tratamento de diabetes do tipo 2 |
| BRPI0514515A (pt) * | 2004-08-17 | 2008-06-10 | Hoffmann La Roche | hidantoìnas substituìdas |
| CN101014345A (zh) | 2004-09-09 | 2007-08-08 | 默克公司 | 三环酰苯胺螺环内酰胺cgrp受体拮抗剂 |
| US7390798B2 (en) * | 2004-09-13 | 2008-06-24 | Merck & Co., Inc. | Carboxamide spirolactam CGRP receptor antagonists |
| CA2579847A1 (en) * | 2004-09-13 | 2006-03-23 | Merck & Co., Inc. | Bicyclic anilide spirolactam cgrp receptor antagonists |
| TW200621766A (en) * | 2004-09-17 | 2006-07-01 | Hoffmann La Roche | Substituted hydantoins |
| JP2009500377A (ja) | 2005-07-08 | 2009-01-08 | ノボ・ノルデイスク・エー/エス | ジシクロアルキルウレア型グルコキナーゼ活性化剤 |
| KR101346902B1 (ko) | 2005-07-09 | 2014-01-02 | 아스트라제네카 아베 | 당뇨병 치료에 있어 glk 활성화제로서 사용하기 위한헤테로아릴 벤즈아미드 유도체 |
| EP1910317B1 (en) | 2005-07-20 | 2013-07-03 | Eli Lilly And Company | 1-amino linked compounds |
| JP2007063225A (ja) | 2005-09-01 | 2007-03-15 | Takeda Chem Ind Ltd | イミダゾピリジン化合物 |
| CA2624102A1 (en) | 2005-09-29 | 2007-04-12 | Sanofi-Aventis | Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals |
| GT200600428A (es) | 2005-09-30 | 2007-05-21 | Compuestos organicos | |
| GT200600429A (es) | 2005-09-30 | 2007-04-30 | Compuestos organicos | |
| ES2393757T3 (es) | 2005-11-17 | 2012-12-27 | Eli Lilly & Company | Antagonistas de receptor de glucagón, preparación y usos terapéuticos |
| EP1948614A2 (en) * | 2005-11-18 | 2008-07-30 | Takeda San Diego, Inc. | Glucokinase activators |
| FR2894962B1 (fr) * | 2005-12-20 | 2008-03-14 | Pharmamens Sarl | Hydantoines a action insulinotropique |
| US7612212B2 (en) * | 2006-02-22 | 2009-11-03 | Hoffmann-La Roche Inc. | Substituted hydantoins |
| EP2001875A2 (en) * | 2006-03-08 | 2008-12-17 | Takeda San Diego, Inc. | Glucokinase activators |
| PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
| EP2049518B1 (en) | 2006-05-31 | 2011-08-31 | Takeda San Diego, Inc. | Indazole and isoindole derivatives as glucokinase activating agents. |
| US20080107725A1 (en) * | 2006-10-13 | 2008-05-08 | Albano Antonio A | Pharmaceutical Solid Dosage Forms Comprising Amorphous Compounds Micro-Embedded in Ionic Water-Insoluble Polymers |
| US8163779B2 (en) | 2006-12-20 | 2012-04-24 | Takeda San Diego, Inc. | Glucokinase activators |
| TW200831081A (en) | 2006-12-25 | 2008-08-01 | Kyorin Seiyaku Kk | Glucokinase activator |
| JP5248477B2 (ja) * | 2007-03-07 | 2013-07-31 | 杏林製薬株式会社 | グルコキナーゼ活性化物質 |
| JP2010521457A (ja) * | 2007-03-12 | 2010-06-24 | メルク・シャープ・エンド・ドーム・コーポレイション | 単環式アニリドスピロラクタムcgrp受容体アンタゴニスト |
| US8173645B2 (en) | 2007-03-21 | 2012-05-08 | Takeda San Diego, Inc. | Glucokinase activators |
| ATE551336T1 (de) * | 2007-08-16 | 2012-04-15 | Hoffmann La Roche | Substituierte hydantoine |
| JP2011506533A (ja) | 2007-12-20 | 2011-03-03 | エフ.ホフマン−ラ ロシュ アーゲー | Mekキナーゼ阻害剤としての置換ヒダントイン |
| US8258134B2 (en) * | 2008-04-16 | 2012-09-04 | Hoffmann-La Roche Inc. | Pyridazinone glucokinase activators |
| KR101608259B1 (ko) | 2008-04-28 | 2016-04-01 | 교린 세이야꾸 가부시키 가이샤 | 시클로펜틸아크릴산아미드 유도체 |
| KR20110018366A (ko) | 2008-05-16 | 2011-02-23 | 다케다 샌디에고, 인코포레이티드 | 글루코키나아제 활성제 |
| US8450494B2 (en) | 2009-06-22 | 2013-05-28 | Cadila Healthcare Limited | Disubstituted benzamide derivatives as glucokinase (GK) activators |
| UA103807C2 (ru) | 2009-07-31 | 2013-11-25 | Кадила Хелткере Лимитед | Замещенные бензамидные производные как активаторы глюкокиназы (gk) |
| CN102959076B (zh) | 2010-03-31 | 2015-09-16 | 斯克里普斯研究所 | 重编程细胞 |
| ES2671881B1 (es) * | 2016-11-11 | 2019-03-25 | Consejo Superior Investigacion | Procedimiento de obtencion de polimeros con grupos isocianato |
| CN112040945A (zh) | 2018-06-12 | 2020-12-04 | Vtv治疗有限责任公司 | 葡萄糖激酶激活剂与胰岛素或胰岛素类似物组合的治疗用途 |
| US12391658B2 (en) | 2020-02-18 | 2025-08-19 | Vtv Therapeutics Llc | Sulfoxide and sulfone glucokinase activators and methods of use thereof |
| CA3181722A1 (en) | 2020-06-08 | 2021-12-16 | Jing TENG | Salts or co-crystals of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid and uses thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5202339A (en) * | 1987-08-28 | 1993-04-13 | Mochida Pharmaceutical Co., Ltd. | Hydantoin derivatives |
| US6320050B1 (en) * | 1999-03-29 | 2001-11-20 | Hoffmann-La Roche Inc. | Heteroaromatic glucokinase activators |
| AU5227001A (en) * | 2000-05-03 | 2001-11-12 | Hoffmann La Roche | Hydantoin-containing glucokinase activators |
-
2001
- 2001-04-23 AU AU5227001A patent/AU5227001A/xx active Pending
- 2001-04-23 DK DK01925563T patent/DK1280801T3/da active
- 2001-04-23 CA CA002407428A patent/CA2407428C/en not_active Expired - Fee Related
- 2001-04-23 CN CNB018089135A patent/CN1209361C/zh not_active Expired - Fee Related
- 2001-04-23 PT PT01925563T patent/PT1280801E/pt unknown
- 2001-04-23 MX MXPA02010746A patent/MXPA02010746A/es active IP Right Grant
- 2001-04-23 JP JP2001580906A patent/JP3842131B2/ja not_active Expired - Fee Related
- 2001-04-23 BR BR0110492-6A patent/BR0110492A/pt not_active Application Discontinuation
- 2001-04-23 ES ES01925563T patent/ES2248309T3/es not_active Expired - Lifetime
- 2001-04-23 WO PCT/EP2001/004555 patent/WO2001083478A2/en not_active Ceased
- 2001-04-23 KR KR10-2002-7014735A patent/KR100505312B1/ko not_active Expired - Fee Related
- 2001-04-23 AT AT01925563T patent/ATE304011T1/de not_active IP Right Cessation
- 2001-04-23 EP EP01925563A patent/EP1280801B1/en not_active Expired - Lifetime
- 2001-04-23 AU AU2001252270A patent/AU2001252270B2/en not_active Ceased
- 2001-04-23 DE DE60113247T patent/DE60113247T2/de not_active Expired - Lifetime
- 2001-04-26 US US09/843,466 patent/US6583288B2/en not_active Expired - Fee Related
- 2001-04-30 AR ARP010102036A patent/AR034253A1/es unknown
- 2001-04-30 PE PE2001000389A patent/PE20011313A1/es not_active Application Discontinuation
- 2001-05-02 UY UY26689A patent/UY26689A1/es not_active Application Discontinuation
- 2001-05-03 EC EC2001004055A patent/ECSP014055A/es unknown
-
2002
- 2002-10-17 ZA ZA200208370A patent/ZA200208370B/en unknown
-
2003
- 2003-06-04 US US10/454,041 patent/US6784298B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20010056191A1 (en) | 2001-12-27 |
| UY26689A1 (es) | 2001-11-30 |
| ES2248309T3 (es) | 2006-03-16 |
| CA2407428A1 (en) | 2001-11-08 |
| AU5227001A (en) | 2001-11-12 |
| US20030225286A1 (en) | 2003-12-04 |
| EP1280801A2 (en) | 2003-02-05 |
| DE60113247D1 (de) | 2005-10-13 |
| WO2001083478A2 (en) | 2001-11-08 |
| WO2001083478A3 (en) | 2002-05-16 |
| DK1280801T3 (da) | 2006-01-23 |
| PE20011313A1 (es) | 2001-12-28 |
| DE60113247T2 (de) | 2006-06-22 |
| EP1280801B1 (en) | 2005-09-07 |
| MXPA02010746A (es) | 2003-03-10 |
| KR100505312B1 (ko) | 2005-08-04 |
| JP3842131B2 (ja) | 2006-11-08 |
| CN1427838A (zh) | 2003-07-02 |
| CN1209361C (zh) | 2005-07-06 |
| CA2407428C (en) | 2010-02-02 |
| KR20020093120A (ko) | 2002-12-12 |
| US6583288B2 (en) | 2003-06-24 |
| JP2003531905A (ja) | 2003-10-28 |
| AR034253A1 (es) | 2004-02-18 |
| ATE304011T1 (de) | 2005-09-15 |
| AU2001252270B2 (en) | 2005-12-15 |
| US6784298B2 (en) | 2004-08-31 |
| ECSP014055A (es) | 2002-01-25 |
| PT1280801E (pt) | 2005-11-30 |
| ZA200208370B (en) | 2004-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0110492A (pt) | Composto, composição farmacêutica que compreende esse composto, processo para a preparação de composição farmacêutica, utilização do composto e processo para a preparação do composto | |
| BR0110573A (pt) | Composto, composição farmacêutica que compreende esse composto, processo para a preparação de uma composição farmacêutica, utilização do composto e processo para o tratamento profilático ou terapêutico e para a preparação do composto | |
| BR0315047A (pt) | Composto, composição fermacêutica que compreende o mesmo, processo para a preparação da composição farmacêutica, utilização dos compostos, método de tratamento e processo para a preparação do composto | |
| BR0200782A (pt) | Compostos para o tratamento da isquemia | |
| UY26694A1 (es) | Activadores de fenil glucocinasa para - arilo o hetero sustituidos | |
| SE0200979D0 (sv) | New compounds | |
| BR9911482A (pt) | Composto, composição farmacêutica, uso do composto, e, processos para o tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto | |
| BR0209127A (pt) | compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos | |
| AR031828A2 (es) | Procedimientos para la preparacion de compuestos espiro-azabiciclicos utiles en terapia | |
| MY136926A (en) | Glucokinase activators | |
| BR0309546A (pt) | Composto, composição farmacêutica que compreende o mesmo, processo para a sua preparação e utilização e método para tratamento profilático ou terapêutico de diabetes do tipo ii | |
| BR0317268A (pt) | Compostos ativadores da pirazina e da piridina glucoquinase 5-substituìda, composição farmacêutica, uso e processo de preparação dos mesmos | |
| BR0212008A (pt) | Uso de um composto ou de um sal, solvato ou pró-medicamento deste, composição farmacêutica, composto ou um sal, solvato ou pró-medicamento deste, e, processo para a preparação deste | |
| TW200510375A (en) | New compounds | |
| BR0209129A (pt) | Compostos, composições farmacêuticas, métodos para tratamento de dores, métodos para modulação de uma resposta farmacológica e usos de compostos | |
| BR0116169A (pt) | Composto, composição farmacêutica que compreende esse composto, processo para a preparação de uma composição farmacêutica, utilização dos compostos, processo para o tratamento profilático ou terapêutico de diabetes do tipo ii e processo para a preparação do composto. | |
| BR0307351A (pt) | Composto, composição farmacêutica, método para tratar uma condição ou estado de doença mediados pela atividade de p38 quinase ou mediados por citocinas produzidas pela atividade de p38 quinase, uso de um composto, e, processo para preparar um composto | |
| BRPI0417684A (pt) | composto, composição farmacêutica, e, uso de um composto | |
| PA8503301A1 (es) | Compuestos para el tratamiento de la isquemia | |
| BR0108678A (pt) | Novos compostos | |
| BR0010716A (pt) | Compostos de fenila substituìdos com atividade imunossupressora e composições farmacêuticas | |
| BR0114092A (pt) | Guanididas de ácido cinámico substituìdas, processos para a sua preparação, sua aplicação como medicamento bem como o medicamento contendo as mesmas | |
| BR0311984A (pt) | Difenilazetidinonas substituìdas cationicamente, processo para a sua preparação, medicamentos contendo estes compostos e sua aplicação | |
| ATE368023T1 (de) | Hydroxydiphenyletherverbindungen | |
| SE0302546D0 (sv) | New compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |